- Subjects who are expected to develop neutropenia following chemotherapy.
- Subjects who require treatment for the prevention of systemic fungal infection.
- Subjects with a history of severe intolerance of azole antifungal agents.
- Subjects with documented bacterial or viral infection at the time of study entry who
are not responding to appropriate treatment against the infection.